CEPI Newsletter

View this email in your browser

CEPI | New vaccines for a safer world

Coalition for Epidemic Preparedness Innovations

Newsletter 27 March 2017

Message from the Interim CEPI CEO

Today CEPI is announcing our second call. This is not a funding call, but a call for information on rapid response platform technologies, in collaboration with the Bill & Melinda Gates Foundation. A new or unknown pathogen will always be on top of the list of epidemic risks to prepare for, and platform technologies will be key to a rapid response in these cases. By using an already validated vaccine platform and substituting or complementing it with a new antigen, the aim is to spare valuable time for development of a vaccine in an outbreak situation. This call for information will be used to inform a call for proposals on platform technologies from CEPI in May this year.

Last week CEPI arranged a scientific meeting on regulatory issues related to Ebola vaccines at the National Academy of Sciences in Washington DC. The meeting gathered around 100 invited participants from vaccine companies, regulators, government agencies and academic institutions discussing regulatory scientific gaps needed to be addresed for the completion of the work on Ebola virus vaccines. The meeting triggered the need for further specific discussions that will be followed up by the CEPI secretariat in order to inform a potential call for proposals on this theme later this year.

Both these two events are important milestones for CEPI, demonstrating that we are progressing fast and well in the work that we have set out to do. At the same time CEPI keeps being highlighted as an important contribution to global health by key actors, like Chancellor Merkel did last week during the Science 20 Dialogue Forum in Halle.

John-Arne Røttingen, Interim CEPI CEO

Request for Information on Rapid Response Platform Technologies for Epidemic Preparedness

CEPI and the Bill and Melinda Gates Foundation are launching a **Request for Information** (RfI) on rapid response vaccine and antibody technologies that could be used to address future emerging diseases.

We request information on technologies related to production of both vaccines and antibody therapeutics. The Request for Information (RFI) will be used to populate that landscape, as well as to influence the development of a Call for Proposals (CFP) by CEPI on rapid response platform technologies specifically for vaccine development. The CEPI CFP is anticipated to be issued in late May 2017.

Read more here

On 22 March CEPI arranged a scientific meeting on regulatory issues related to Ebola vaccines at the National Academy of Sciences in Washington DC. Around 100 invited participants from vaccine companies, regulators, government agencies and academic institutions gathered to discuss regulatory scientific gaps needed to be addressed in order to complete the work on Ebola virus vaccines. The meeting exposed a need for further specific discussions that will be followed up by the CEPI secretariat in order to inform a potential call for proposals on this theme later this year.

Call for participation

Germany assumed the G20 presidency on December 1, 2016 and has prioritized global health as an area where the G20 can make a substantial contribution to achieving the objectives of Agenda 2030. In this regard, CEPI is co-hosting an event in Berlin 28 April where interested individuals and organizations can engage in roundtable discussions on global health innovation in the G20 to respond to this call. The title for the meeting is "Research for Impact' & the G20: How can global health innovation drive sustainable development?"

Delegates are invited to participate and discuss with co-hosts, stakeholders, politicians, think tanks, NGO's and representatives from G20 and G77 countries. Please see this link for more information. RSVP can be communicated to G20GlobalHealth@sovereignstrategy.com for expression of interest to participate.

.

CEPI 2 pager in Portuguese

The CEPI 2 pager is now available in Portuguese and can be downloaded here.

www.cepi.net   info@cepi.net